BioLineRx, High Potential Near Term Catalysts, Analysts Review and Target

BioLineRx Ltd. (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.


The company’ shares continue to zoom backed by the favorable impact of its recent announcements, and many high-potential near-term catalysts that are lined up for 2018/2019. In fact, the positive outcomes of its clinical developments, that continue to support the therapeutic potential of its drug candidates, have also made BLRX a lucrative takeover play for some larger participants in the industry.

Furthermore, from a liquidity and financial standpoint, BLRX’ financial footing continues to remain stable and provides it with resources necessary to fully execute on its operational plan towards the first half of 2020.



Our members have booked up to 800% with our recent (2018) NASDAQ and NYSE small cap alerts. We will be initiating coverage on another exciting small cap security mid-week this week (10/14/18). View our recent picks, track record, look at this week’s report and sign up for our real time mobile/text alerts here –


On October 3rd, the company announced an agreement with Biokine Therapeutics to increase BioLineRx’s stake in its lead oncology platform, BL-8040, a CXCR4 antagonist currently in late stage clinical development in both solid tumor and hematological indications, including stem cell mobilization (SCM), acute myeloid leukemia (AML) and immunotherapy for multiple types of solid tumors. As a result of the transaction, BioLineRx will increase its economic stake in the program to 80% from the previous level of 60%. BioLineRx licensed the exclusive worldwide rights to BL-8040 from Biokine Therapeutics in 2012.


Under the terms of the agreement, upon closing of the transaction, BioLineRx will pay Biokine Therapeutics an upfront payment of $10 million in cash plus $5 million in restricted BioLineRx shares. Biokine is also eligible to receive up to a total of $5 million in future milestone payments. The $10 million upfront payment is being financed in full via the receipt of $10 million in debt financing from Kreos Capital.


As the company works to bring novel cancer treatments to patients in need, the management believes that this transaction reflects their strong commitment to this program and better positions BLRX to create significant long-term value for its stakeholders.


Before this, on August 13, 2018, the company reported its financial results and business updates for the second quarter ended June 30, 2018.


Highlights and achievements during the second quarter of 2018 and to date: BLRX Continued to make progress on multiple clinical trials and its lead oncology program, BL-8040:

  • Positive data from successful completion of the first lead-in patient cohort of the GENESIS trial, a double-blind, placebo-controlled, Phase 3 trial comparing BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF), to G-CSF alone, for the mobilization of hematopoietic stem cells (HSCs) used for autologous transplantation in multiple myeloma patients.
  • Expansion of immuno-oncology collaboration with Merck & Co., Inc., Kenilworth, N.J. (Merck), supporting a Phase 2a program investigating BL-8040 in combination with KEYTRUDA in pancreatic cancer patients.
  • Presentation at the 2018 European Hematology Association (EHA) Conference of very encouraging long-term overall survival results in Phase 2a trial in relapsed/refractory AML, demonstrating that the combination of BL-8040 with high-dose Cytarabine (HiDAC) significantly improved overall survival, compared with historical data for HiDAC monotherapy;
  • Grant of European patent covering the use of BL-8040 with Cytarabine for treating AML; valid through March 2034 with up to five years’ patent term extension.


The Company also announced advancements made in its 2nd immuno-oncology compound, AGI-134   

  • Initiation of multicenter, open-label Phase 1/2a study in the UK and Israel, with possible expansion to the US and additional countries in Europe in 2019; study will evaluate the safety and tolerability of AGI-134, as a monotherapy and in combination with an immune checkpoint inhibitor, in unresectable metastatic solid tumors.


Over the next few quarters, the company has promising milestones/Catalysts in the next 18 months:

  • Top-line results in immuno-oncology Phase 2a COMBAT study in pancreatic cancer for BL-8040 in combination with KEYTRUDA, under collaboration with Merck, to be presented at the European Society for Medical Oncology (ESMO) Congress in October 2018;
  • Partial results in Phase 1b/2 study in pancreatic cancer under Genentech immuno-oncology collaboration, investigating BL-8040 in combination with Genentech’s atezolizumab, expected in H2 2018;
  • Potential interim analysis of Phase 2b BLAST study in AML consolidation in mid-2019:
  • Results from the additional cohort in Phase 2a COMBAT study under the expansion of Merck collaboration, investigating a triple combination of BL-8040, KEYTRUDA and chemotherapy in pancreatic cancer, by the end of 2019


Upcoming events:

  • October 19, 2018 – ESMO 2018 Congress
  • January 7, 2018 – JPM/Biotech Showcase


Investment highlights and target price.


Analyst tracking the stock believes that the company business profile is marked by significant revenue potential & the company’ strong fundamentals are well poised for value creation. Per, their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 117.39%. The high price target for BLRX is $4.00, and the low-price target for BLRX is $2.00. Considering all this, the company is in an extremely favorable risk-reward position, and value investors should consider exposure in this sector as the backdrop remains favorable.


Below are the excerpts of recent analyst rating on the script:

As per


About the Product: BioLineRx’s leading therapeutic candidates are: BL-8040, a multi-therapy platform, which has completed a Phase 2a study for relapsed/refractory AML, is in the midst of a Phase 2b study as an AML consolidation treatment and has initiated a Phase 3 study in stem cell mobilization for autologous transplantation; and AGI-134, an immunotherapy treatment in development for multiple solid tumors, which has recently initiated a Phase 1/2a study.


Strategic collaboration: In addition, BioLineRx has a strategic collaboration with Novartis for the co-development of selected Israeli-sourced novel drug candidates; a collaboration agreement with MSD (known as Merck in the US and Canada), on the basis of which the Company is conducting a Phase 2a study in pancreatic cancer using the combination of BL-8040 and Merck’s KEYTRUDA®; and a collaboration agreement with Genentech, a member of the Roche Group, to investigate the combination of BL-8040 and Genentech’s atezolizumab in several Phase 1b/2 studies for multiple solid tumor indications and AML.



Recent accomplishments and upcoming opportunities at a glance:

Second Quarter 2018 Highlights:

  • R&D: Research and development expenses for the three months ended June 30, 2018, were $4.5 million, an increase of $0.4 million, or 10.4%, compared to $4.1 million for the three months ended June 30, 2017.


  • Operating Loss: The Company’s operating loss for the three months ended June 30, 2018, amounted to $5.7 million, compared with an operating loss of $5.2 million for the corresponding 2017 period.
  • Net Loss: The Company’s net loss for the three months ended June 30, 2018, amounted to $4.8 million, compared with a net loss of $4.9 million for the corresponding period. The Company’s net loss for the six months ended June 30, 2018, amounted to $11.0 million, compared with a net loss of $9.8 million for the corresponding 2017 period.
  • Liquidity and financial flexibility: The Company held $41.1 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2018.


Key risk factors and potential stock drivers:

  • Successful completion of the upcoming milestones would lead future direction for the company. Any adversities might adversely impact the overall investor sentiments.
  • The company operation is still in the clinical development stage. Therefore, its ability to maintain its present strong liquidity and financial flexibility and to fund its incremental capital requirements without any major cost or time overruns would remain a critical challenge for the company.
  • BLRX operates in a competitive and dynamic space and only time would differentiate between real winners and laggards. Some of its competitors may have longer operating histories and greater resources than BLRX.
  • As far as choosing an option with a relative advantage is concerned, BLRX is preferred choice with upside potential.


Stock Performance


  • On Tuesday, Oct 16th, 2018, BLRX was at $1.45, on traded volume of 1.9 million shares exchanging hands. Market capitalization is $146.181 million. The current RSI is 71.49
  • In the past 52 weeks, shares of BLRX have traded as low as $0.78 and as high as $1.84
  • At $1.45, shares of BLRX are trading above its 50-day moving average (MA) at $1.02 and above its 200-day moving average (MA) at $0.96
  • The present support and resistance levels for the stock are at $1.26 & $1.50 respectively.



Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
17B Disclosure
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.